What InnovAge (INNV) Said on Its Q1 Earnings Call

InnovAge (INNV) reported Q1 cost of care rose 12.7% to $85.5M, citing growth and higher expenses. The company is investing in care teams and technology to reduce costs. InnovAge reaffirmed its fiscal 2027 guidance, expecting revenue of $1.05B-$1.085B and adjusted EBITDA of $105M-$115M. Medicare rates are expected to increase 1.5%-2% from Jan 1, 2024.

Original reporting
Published Nov 4, 2026, 1:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 1:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What InnovAge (INNV) Said on Its Q1 Earnings Call — source image
Decision brief

The 30-second read

$INNVNeutralMed
01

Why it matters

Management attributed Q1 cost-of-care increases to member-month growth and higher per-participant costs, while describing operational steps to reduce assisted-living and nursing-facility costs. It also provided a detailed view of how V28 affects its PACE population and reiterated FY2027 guidance with a planned shift in the V28 blend during fiscal Q3.

02

Market read

The key tradable inputs are the reaffirmed FY2027 ranges, the expected Medicare rate increase effective Jan. 1, and the timing of the V28 blend shift, which together shape near-term margin and reimbursement expectations.

03

What to watch

The article highlights cost increases (salaries, pharmacy third-party fees, contract services, fleet costs) and de novo center losses; traders may underweight how these could pressure margins even with stable revenue guidance.

Relevance 7/10Novelty 6/10Timing: post-Q1 earnings call, ahead of fiscal Q3 V28 blend shift

Background

InnovAge operates PACE programs for older adults and is transitioning its Medicare risk-adjustment exposure under the V28 model.

Company-level read

Ticker impact

$INNVNeutralMedium confidence
Context

InnovAge reaffirmed FY2027 guidance and discussed V28 Medicare risk-adjustment transition, including expected 1.5% to 2% Medicare rate increase effective Jan. 1.

Expected impact

Likely modest support as investors weigh reaffirmed FY2027 targets against ongoing reimbursement and cost headwinds from the V28 transition.

Evidence & confidence

The article provides specific guidance ranges, V28 blend timing (90/10 to 50/50 in fiscal Q3), and cost drivers, but it does not introduce a new transaction or surprise print beyond the earnings-call disclosures.

Market effects

PACE and Medicare Advantage-adjacent healthcare operators may face similar reimbursement-model transition scrutiny, increasing focus on encounter-data quality and diagnosis mix.

No specific regional impact disclosed beyond market-level provider network investments.

Limited, as the disclosures are US Medicare reimbursement and company-specific guidance.

Counterpoint

Reaffirmed guidance may still embed optimistic assumptions about V28 phase-in reimbursement and cost containment, so downside risk remains if encounter-data submission or diagnosis mix deteriorates.

Key entities

  • InnovAge

    NASDAQ-listed PACE healthcare services provider that reaffirmed FY2027 guidance and discussed V28 Medicare risk-adjustment transition.

  • V28 Medicare risk-adjustment model

    New Medicare Advantage risk-adjustment framework discussed as creating reimbursement pressure for plans, with InnovAge arguing PACE eligibility criteria differ.

  • Epic, data and analytics

    Stated priorities under InnovAge 3.0 to support care teams and productivity, plus early-stage AI assessment for clinical decision support.

Related articles

$INNVMed

InnovAge settles DOJ civil claims for $37 million

InnovAge Holding Corp. (INNV) settled civil claims with the DOJ for $37 million, covering alleged conduct from 2016 to 2022. The company did not admit wrongdoing. InnovAge provides senior healthcare programs and has invested in compliance and operations. As of September 2026, it served 8,420 participants across 20 centers in six states.

$INNVMed

InnovAge (INNV) Q1 2027 Earnings Call Transcript

InnovAge (INNV) reported Q1 2027 revenue of $264.8M, up 12.1% YoY, and adjusted EBITDA of $31.3M, up 75%. The company cited growth in census and profitability, investments in clinical and operational capabilities, and plans for expansion. Management discussed the impact of the V28 Medicare risk adjustment model, noting differences between PACE and Medicare Advantage.

$INNVHigh

INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026

InnovAge Holding Corp. (INNV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026 DENVER, CO., November 3, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare